Monogram Announces Conference Call

LEADING HIV PHYSICIAN, Dr. DAVID HARDY, TO DISCUSS CLINICAL USE OF THE
TROFILE(TM) ASSAY AND SELZENTRY(TM) IN CONJUNCTION WITH THE THIRD QUARTER 2008
FINANCIAL RESULTS CONFERENCE CALL

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference
call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the
clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's CCR5
antagonist, Selzentry(TM). Monogram will also review its third quarter 2008
financial results. The call will be hosted by William D. Young, Chairman & CEO
of Monogram. Dr. David Hardy will participate in the call. Dr. Hardy is
Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and
is Associate Professor of Medicine-in-Residence at the David Geffen School of
Medicine at UCLA.
To participate in the live teleconference, please call (877) 604-9672, or
(719) 325-4896 for international callers, fifteen minutes before the
conference begins. Live audio of the call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the general public. Access to live and archived audio of the
conference call will be available on the Investor Relations section at
http://www.monogrambio.com. Following the live broadcast, a replay of the call
will also be available at (888) 203-1112 or (719) 457-0820 for international
callers, through Sunday, November 9, 2008. The replay passcode is 4461917.
The information provided on the teleconference is only accurate at the time of
the conference call, and Monogram will take no responsibility for providing
updated information except as required by law.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering, developing
and marketing innovative products to guide and improve treatment of serious
infectious diseases and cancer. The Company's products are designed to help
doctors optimize treatment regimens for their patients that lead to better
outcomes and reduced costs. The Company's technology is also being used by
numerous biopharmaceutical companies to develop new and improved anti-viral
therapeutics and vaccines as well as targeted cancer therapeutics. More
information about the Company and its technology can be found on its web site
at www.monogrambio.com.
Trofile is a trademark of Monogram Biosciences, Inc. Selzentry is a
trademark of Pfizer Inc.
contacts: Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624-4576 Tel: 415 677-2700
amerriweather@monogrambio.com jeremiah.hall@fkhealth.com

SOURCE Monogram Biosciences, Inc.

Alfred G. Merriweather, Chief Financial Officer of Monogram Biosciences, Inc.,
+1-650-624-4576, amerriweather@monogrambio.com; or Jeremiah Hall of Feinstein
Kean Healthcare for Monogram Biosciences, Inc., +1-415-677- 2700,
jeremiah.hall@fkhealth.com